Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for AC Immune (ACIU) over the last 5 years, with Sep 2024 value amounting to $3.6 million.

  • AC Immune's Gains from Investment Securities fell 35.83% to $3.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.8 billion, marking a year-over-year increase of 32373.90%. This contributed to the annual value of -$14,227 for FY2021, which is 120.10% down from last year.
  • Latest data reveals that AC Immune reported Gains from Investment Securities of $3.6 million as of Q3 2024, which was down 99.80% from $1.8 billion recorded in Q2 2024.
  • Over the past 5 years, AC Immune's Gains from Investment Securities peaked at $1.8 billion during Q2 2024, and registered a low of -$1.3 billion during Q4 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $216,168 (2022), whereas its average is $183.9 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first slumped by 25,056.60% in 2021, then spiked by 1,686,060.14% in 2024.
  • Quarterly analysis of 5 years shows AC Immune's Gains from Investment Securities stood at $5.1 million in 2020, then crashed by 25,056.60% to -$1.3 billion in 2021, then spiked by 99.99% to -$154,268 in 2022, then crashed by 3,509.88% to -$5.6 million in 2023, then crashed by 35.83% to $3.6 million in 2024.
  • Its Gains from Investment Securities stands at $3.6 million for Q3 2024, versus $1.8 billion for Q2 2024 and $2.3 million for Q1 2024.